<p>箭头制药（NASDAQ:ARWR - 获取免费报告）在周五向投资者发布的报告中，被华尔街 Zen 的股票研究人员从 “持有” 评级上调至 “买入” 评级。</p>
<ul>
<li>想要在生物技术领域获得多元化的上行潜力？查看 LABU</li>
</ul>
<p>其他股票研究分析师最近也对该公司发布了报告。花旗集团将箭头制药的目标价格从 21.00 美元下调至 17.00 美元，并在 5 月 13 日的报告中对该股票给予 “中性” 评级。HC Wainwright 在 5 月 20 日的研究报告中重申了 “买入” 评级，并对箭头制药的股票设定了 80.00 美元的目标价格。B. Riley 在 2 月 14 日的研究报告中重申了 “买入” 评级，并将箭头制药的股票目标价格设定为 38.00 美元（之前为 51.00 美元）。加拿大皇家银行在 2 月 11 日的研究报告中重申了 “跑赢大盘” 评级，并将箭头制药的股票目标价格设定为 42.00 美元。最后，Chardan Capital 在 5 月 13 日的研究报告中重申了 “买入” 评级，并将箭头制药的股票目标价格设定为 60.00 美元。两位股票研究分析师对该股票给予了持有评级，七位分析师对该公司的股票给予了买入评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价格为 43.71 美元。</p>
<p><strong>阅读我们关于 ARWR 的最新研究报告</strong></p>
<h2>箭头制药上涨 2.1%</h2>
<p>在周五的交易时段，NASDAQ ARWR 上涨 0.35 美元，达到 16.81 美元。该公司股票的交易量为 1,235,465 股，而其平均交易量为 1,523,956 股。该公司的 50 日移动平均线为 13.72 美元，200 日移动平均线为 17.35 美元。箭头制药的 12 个月低点为 9.57 美元，12 个月高点为 30.41 美元。该公司的市值为 23.2 亿美元，市盈率为-3.25，贝塔值为 0.96。该公司的债务与股本比率为 7.27，速动比率为 6.09，流动比率为 6.09。</p>
<p>箭头制药（NASDAQ:ARWR - 获取免费报告）最近于 5 月 12 日发布了季度财报。这家生物技术公司报告的季度每股收益为 2.75 美元，超出分析师一致预期的（0.06 美元）2.81 美元。该公司在本季度的收入为 5.4271 亿美元，而分析师预期为 1.1627 亿美元。去年同期，该公司每股收益为（1.02 美元）。分析师预计箭头制药在当前财政年度将发布-2.42 美元的每股收益。</p>
<h2>内部买卖</h2>
<p>在其他消息中，首席执行官 Christopher Richard Anzalone 在 4 月 9 日的交易中出售了 40,322 股公司的股票。该股票的平均售价为 10.07 美元，总交易额为 406,042.54 美元。出售完成后，首席执行官现在直接持有 4,022,055 股公司的股票，价值 40,502,093.85 美元。这代表着他们持有的股票减少了 0.99%。该出售在向 SEC 提交的文件中披露，文件可在 SEC 网站上获取。内部人士在过去三个月内出售了 142,547 股公司股票，价值 1,764,709 美元。当前 4.30% 的股票由内部人士持有。</p>
<h2>机构投资者对箭头制药的看法</h2>
<p>对冲基金最近调整了对该股票的持有。Raymond James Financial Inc.在第四季度购买了价值 651,000 美元的箭头制药新股份。法国巴黎银行金融市场在第四季度将其在箭头制药的持股增加了 59.5%。法国巴黎银行金融市场目前持有 88,029 股生物技术公司的股票，价值 1,655,000 美元，此前在上个季度购买了 32,841 股。Empowered Funds LLC 在第四季度获得了箭头制药的新头寸，价值 268,000 美元。Slate Path Capital LP 在第四季度将其在箭头制药的持股增加了 7.1%。Slate Path Capital LP 目前持有 5,232,000 股生物技术公司的股票，价值 98,362,000 美元，此前在该期间购买了 347,000 股。最后，KLP Kapitalforvaltning AS 在第四季度获得了箭头制药的新头寸，价值 434,000 美元。62.61% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>箭头制药公司简介</h2>
<p>（获取免费报告）</p>
<p>箭头制药公司在美国开发用于治疗难治性疾病的药物。该公司的产品管线包括 Plozasiran，目前正在进行 2b 期和一项 3 期临床试验，以治疗高甘油三酯血症、混合性血脂异常和乳糜微粒血症；Zodasiran 正在进行 2b 期临床试验，以治疗血脂异常和高甘油三酯血症；ARO-PNPLA3 正在进行 1 期临床试验，以治疗非酒精性脂肪性肝炎患者；ARO-RAGE 正在进行 1/2a 期临床试验，以治疗炎症性肺部疾病；ARO-MUC5AC 正在进行 1/2a 期临床试验，以治疗粘液阻塞性肺病。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比箭头制药更好</li>
<li>如何在购买前评估一只股票</li>
<li>大规模的石油供应减少可能意味着这三只能源股票的上行潜力</li>
<li>三只国防股票将受益于军事支出的增加</li>
<li>三只股票获得分析师罕见的双重升级</li>
<li>如何从成长投资中获利</li>
<li>这家银行巨头刚刚获得了 90 美元的目标价格上调</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在箭头制药吗？</h2>
<p>在考虑箭头制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而箭头制药并不在名单上。</p>
<p>虽然箭头制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

箭头制药

<p>华尔街禅将箭头制药（NASDAQ:ARWR）的评级从 “持有” 上调至 “买入”。花旗集团将其目标价从 21.00 美元下调至 17.00 美元，维持 “中性” 评级。其他分析师，包括 HC Wainwright 和 B. Riley，重申了 “买入” 评级，目标价分别为 80.00 美元和 38.00 美元。该股上涨 2.1%，报 16.81 美元，平均评级为 “适度买入”，目标价为 43.71 美元。箭头制药报告的每股收益为 2.75 美元，超出预期，上一季度的收入为 5.4271 亿美元</p>

<p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a note issued to investors on Friday.</p>
<div class="lb-trans"><p>箭头制药（NASDAQ:ARWR - 获取免费报告）在周五向投资者发布的报告中，被华尔街 Zen 的股票研究人员从 “持有” 评级上调至 “买入” 评级。</p>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想要在生物技术领域获得多元化的上行潜力？查看 LABU</li>
</ul>
</div><p>Other equities research analysts also recently issued reports about the company. Citigroup dropped their target price on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a &#34;neutral&#34; rating on the stock in a report on Tuesday, May 13th. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 20th. B. Riley restated a &#34;buy&#34; rating and set a $38.00 price objective (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Royal Bank of Canada restated an &#34;outperform&#34; rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Finally, Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $43.71.</p>
<div class="lb-trans"><p>其他股票研究分析师最近也对该公司发布了报告。花旗集团将箭头制药的目标价格从 21.00 美元下调至 17.00 美元，并在 5 月 13 日的报告中对该股票给予 “中性” 评级。HC Wainwright 在 5 月 20 日的研究报告中重申了 “买入” 评级，并对箭头制药的股票设定了 80.00 美元的目标价格。B. Riley 在 2 月 14 日的研究报告中重申了 “买入” 评级，并将箭头制药的股票目标价格设定为 38.00 美元（之前为 51.00 美元）。加拿大皇家银行在 2 月 11 日的研究报告中重申了 “跑赢大盘” 评级，并将箭头制药的股票目标价格设定为 42.00 美元。最后，Chardan Capital 在 5 月 13 日的研究报告中重申了 “买入” 评级，并将箭头制药的股票目标价格设定为 60.00 美元。两位股票研究分析师对该股票给予了持有评级，七位分析师对该公司的股票给予了买入评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价格为 43.71 美元。</p>
</div><p><strong>Read Our Latest Research Report on ARWR</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 ARWR 的最新研究报告</strong></p>
</div><h2>Arrowhead Pharmaceuticals Trading Up 2.1%</h2>
<div class="lb-trans"><h2>箭头制药上涨 2.1%</h2>
</div><p>NASDAQ ARWR traded up $0.35 during trading hours on Friday, hitting $16.81. 1,235,465 shares of the company's stock were exchanged, compared to its average volume of 1,523,956. The business's 50 day moving average is $13.72 and its 200-day moving average is $17.35. Arrowhead Pharmaceuticals has a 12-month low of $9.57 and a 12-month high of $30.41. The firm has a market capitalization of $2.32 billion, a P/E ratio of -3.25 and a beta of 0.96. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09.</p>
<div class="lb-trans"><p>在周五的交易时段，NASDAQ ARWR 上涨 0.35 美元，达到 16.81 美元。该公司股票的交易量为 1,235,465 股，而其平均交易量为 1,523,956 股。该公司的 50 日移动平均线为 13.72 美元，200 日移动平均线为 17.35 美元。箭头制药的 12 个月低点为 9.57 美元，12 个月高点为 30.41 美元。该公司的市值为 23.2 亿美元，市盈率为-3.25，贝塔值为 0.96。该公司的债务与股本比率为 7.27，速动比率为 6.09，流动比率为 6.09。</p>
</div><p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $2.81. The firm had revenue of $542.71 million during the quarter, compared to analysts' expectations of $116.27 million. During the same quarter last year, the business earned ($1.02) earnings per share. As a group, analysts anticipate that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>箭头制药（NASDAQ:ARWR - 获取免费报告）最近于 5 月 12 日发布了季度财报。这家生物技术公司报告的季度每股收益为 2.75 美元，超出分析师一致预期的（0.06 美元）2.81 美元。该公司在本季度的收入为 5.4271 亿美元，而分析师预期为 1.1627 亿美元。去年同期，该公司每股收益为（1.02 美元）。分析师预计箭头制药在当前财政年度将发布-2.42 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, CEO Christopher Richard Anzalone sold 40,322 shares of the company's stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $10.07, for a total transaction of $406,042.54. Following the completion of the sale, the chief executive officer now directly owns 4,022,055 shares of the company's stock, valued at $40,502,093.85. This represents a 0.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold 142,547 shares of company stock worth $1,764,709 in the last three months. 4.30% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席执行官 Christopher Richard Anzalone 在 4 月 9 日的交易中出售了 40,322 股公司的股票。该股票的平均售价为 10.07 美元，总交易额为 406,042.54 美元。出售完成后，首席执行官现在直接持有 4,022,055 股公司的股票，价值 40,502,093.85 美元。这代表着他们持有的股票减少了 0.99%。该出售在向 SEC 提交的文件中披露，文件可在 SEC 网站上获取。内部人士在过去三个月内出售了 142,547 股公司股票，价值 1,764,709 美元。当前 4.30% 的股票由内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对箭头制药的看法</h2>
</div><p>Hedge funds have recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at $651,000. BNP Paribas Financial Markets lifted its holdings in shares of Arrowhead Pharmaceuticals by 59.5% during the fourth quarter. BNP Paribas Financial Markets now owns 88,029 shares of the biotechnology company's stock valued at $1,655,000 after purchasing an additional 32,841 shares during the last quarter. Empowered Funds LLC acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter valued at $268,000. Slate Path Capital LP raised its position in Arrowhead Pharmaceuticals by 7.1% during the fourth quarter. Slate Path Capital LP now owns 5,232,000 shares of the biotechnology company's stock valued at $98,362,000 after buying an additional 347,000 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter valued at $434,000. 62.61% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对冲基金最近调整了对该股票的持有。Raymond James Financial Inc.在第四季度购买了价值 651,000 美元的箭头制药新股份。法国巴黎银行金融市场在第四季度将其在箭头制药的持股增加了 59.5%。法国巴黎银行金融市场目前持有 88,029 股生物技术公司的股票，价值 1,655,000 美元，此前在上个季度购买了 32,841 股。Empowered Funds LLC 在第四季度获得了箭头制药的新头寸，价值 268,000 美元。Slate Path Capital LP 在第四季度将其在箭头制药的持股增加了 7.1%。Slate Path Capital LP 目前持有 5,232,000 股生物技术公司的股票，价值 98,362,000 美元，此前在该期间购买了 347,000 股。最后，KLP Kapitalforvaltning AS 在第四季度获得了箭头制药的新头寸，价值 434,000 美元。62.61% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Arrowhead Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>箭头制药公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.</p>
<div class="lb-trans"><p>箭头制药公司在美国开发用于治疗难治性疾病的药物。该公司的产品管线包括 Plozasiran，目前正在进行 2b 期和一项 3 期临床试验，以治疗高甘油三酯血症、混合性血脂异常和乳糜微粒血症；Zodasiran 正在进行 2b 期临床试验，以治疗血脂异常和高甘油三酯血症；ARO-PNPLA3 正在进行 1 期临床试验，以治疗非酒精性脂肪性肝炎患者；ARO-RAGE 正在进行 1/2a 期临床试验，以治疗炎症性肺部疾病；ARO-MUC5AC 正在进行 1/2a 期临床试验，以治疗粘液阻塞性肺病。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Arrowhead Pharmaceuticals</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names</li>
<li>3 Defense Stocks Set to Benefit From Increased Military Spending</li>
<li>3 Stocks Getting Rare Double Upgrades From Analysts</li>
<li>How to Profit From Growth Investing</li>
<li>This Banking Giant Just Got a $90 Price Target Upgrade</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比箭头制药更好</li>
<li>如何在购买前评估一只股票</li>
<li>大规模的石油供应减少可能意味着这三只能源股票的上行潜力</li>
<li>三只国防股票将受益于军事支出的增加</li>
<li>三只股票获得分析师罕见的双重升级</li>
<li>如何从成长投资中获利</li>
<li>这家银行巨头刚刚获得了 90 美元的目标价格上调</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ARWR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在箭头制药吗？</h2>
</div><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑箭头制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而箭头制药并不在名单上。</p>
</div><p>While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然箭头制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

箭头制药（NASDAQ:ARWR）被华尔街 Zen 升级为买入评级